Identification of circulating microRNAs as potential biomarkers for hepatic necroinflammation in patients with autoimmune hepatitis

Chisato Saeki 1,2, Juntaro Matsuizaki,3,4 Masahiko Kuroda,5 Koji Fujita,5 Makiko Ichikawa,6 Satoko Takizawa,6 Keiko Takano,1 Tsunekazu Oikawa,1 Yasuni Nakanuma,7 Masayuki Saruta,1 Takahiro Ochiya,3,8 Akihito Tsubota9

ABSTRACT

Objective MicroRNAs (miRNAs) are implicated in the pathogenesis of autoimmune diseases and could be biomarkers of disease activity. This study aimed to identify highly expressed circulating miRNAs in patients with autoimmune hepatitis (AIH) and to evaluate their association with clinical characteristics.

Methods Microarray analyses were performed, and miRNA expression profiling for AIH, primary biliary cholangitis (PBC) and overlap syndrome (OS) using the serum of patients and healthy individuals was done. Samples were divided into discovery and test sets to identify candidate miRNAs that could discriminate AIH from PBC; the former included 21 AIH and 23 PBC samples, while the latter included five AIH and eight PBC samples.

Results Among 11 candidate miRNAs extracted in the discovery set, 4 (miR-3196, miR-6125, miR-4725–3p and miR-4634) were specifically and highly expressed in patients with AIH in the test set. These four miRNAs discriminated AIH from PBC; the former included 21 AIH and 23 PBC samples, while the latter included five AIH and eight PBC samples.

Conclusion These circulating miRNAs are suggested to reflect hepatic necroinflammatory activity and serve as AIH-related and treatment-responsive biomarkers. These miRNAs could be beneficial in developing new therapeutic strategies for AIH.

INTRODUCTION

Autoimmune hepatitis (AIH) is a progressive, chronic, autoimmune liver disease characterised by elevated serum transaminase, autoantibodies, hyperglobulinaemia and interface hepatitis on histology.1–3 Although environmental, genetic and epigenetic factors and T cell-mediated immune responses are considered the pathogenesis of AIH, the molecular mechanisms underlying the disease have not been clearly elucidated.4 5 Therefore, diagnostic biomarkers and radical treatments specific for AIH have not yet been developed.3,5
Repeat liver biopsies are useful in assessing disease activity and treatment response; however, these are invasive, time-consuming and burdensome to patients. Therefore, in real-world clinical settings, clinical remission is assessed based on biochemical findings, such as the normalization of transaminase and IgG levels. Of note, approximately half of AIH patients with serum parameter normalization after immunosuppressive treatment have persistent histological activity on liver biopsy specimens, which is associated with fibrosis progression and poor prognosis. Therefore, to develop a novel treatment and improve the liver-related mortality in patients with AIH, it is important to better understand the molecular mechanisms underlying the disease and to identify molecules that sensitively reflect histological disease activity.

Primary biliary cholangitis (PBC) is another autoimmune liver disease characterized by the destruction of small intrahepatic bile ducts, progressive cholestasis, and the presence of highly specific serum antimitochondrial antibodies (AMAs). Some patients with PBC manifest the features of AIH and are commonly classified as having so-called ‘overlap syndrome (OS)’. OS has a frequency of 7%–13% in patients with autoimmune liver disease. Of note, patients with OS are more likely to have oesophageal varices, gastrointestinal bleeding, ascites, hepatic failure and/or liver transplantation compared with those with typical PBC. Therefore, the standard treatments for both PBC (such as ursodeoxycholic acid (UDCA)) and AIH (such as corticosteroids) are required to achieve a complete treatment response in most patients with OS.

MicroRNAs (miRNAs) constitute a class of small noncoding RNAs that directly bind to the 3′ untranslated regions of specific target genes, thereby inducing post-transcriptional inhibition. miRNAs play a crucial role in various biological processes, including tissue development and differentiation, immunity, cell proliferation, apoptosis and oncogenesis. Their dysregulation is associated with liver diseases, such as viral hepatitis, alcoholic liver disease, non-alcoholic fatty liver disease and hepatocellular carcinoma. Therefore, elucidating the mechanisms underlying miRNA dysregulation could provide new therapeutic strategies for liver diseases. Circulating RNAs, which are protected from RNases and remain stable in blood, are attractive, non-invasive biomarkers for disease diagnosis and disease stage/activity determination. However, only few studies have evaluated the expression profiles of circulating miRNAs in patients with AIH.

The aim of this study was to identify miRNAs that were highly expressed in patients with AIH by comparing the circulating miRNA profiles of untreated patients with AIH, PBC and OS and healthy controls. Furthermore, changes in the expression levels of identified miRNAs prior to and after treatment were assessed, and their association with treatment response was evaluated.

METHODS
Participants and samples
In this study, 57 treatment-naïve patients with AIH (n=28) or PBC (n=29) and 7 patients with OS at the Jikei University School of Medicine (Tokyo, Japan) and Fuji City General Hospital (Shizuoka, Japan) were enrolled. Twenty-seven healthy volunteers who underwent routine medical check-up at the Jikei University School of Medicine were recruited as controls. They all had normal alanine aminotransferase (ALT;≤35 U/L) and gamma-glutamyltransferase (≤50 U/L) levels with no history of significant diseases. Patients with other liver diseases, such as alcoholic liver disease, drug-induced liver disease, viral hepatitis and non-alcoholic steatohepatitis, were excluded.

Serum samples were collected from patients at the time of diagnosis or exacerbation of the disease and from healthy volunteers at the time of consent. In addition, paired samples were obtained from 21 of the 28 patients with AIH at least 3 months after treatment, from 23 of the 29 patients with PBC at least 12 months after treatment, and from all of the seven patients with OS at least 6 months after additional treatment. All serum samples were stored at −80 °C until analysis. Written informed consent was obtained from each patient. In cases where serum samples had already been stored in another approved study, participants were notified of the opportunity to opt out of the study through the website of each institution.

Diagnosis and treatment
AIH was diagnosed based on the revised International Autoimmune Hepatitis Group criteria. The patients in this study were diagnosed as having probable or definite AIH and were treated with prednisolone alone (0.6–1.0mg/kg/day). We defined remission of AIH as the normalization of ALT and IgG (≤1700mg/dL) levels. Diagnosis of PBC was made if patients met any one of the following criteria: (1) biochemical evidence of cholestasis and histological evidence of chronic non-suppurative destructive cholangitis; (2) the presence of AMA with histologically compatible PBC features and (3) the presence of AMA with PBC clinical features and course characteristics, irrespective of histological findings. All patients with PBC were treated with UDCA (13–15mg/kg/day) or UDCA plus bezafibrate (400mg/day). In this study, biochemical response to these treatments was defined according to the Barcelona criteria, that is, an alkaline phosphate (ALP) decrease of >40% of baseline values or normal ALP levels (≤325 U/L) after 12 months of treatment. OS was diagnosed according to the Paris criteria. Six patients with OS were treated with a combination of prednisolone and UDCA, and the remaining one was treated with UDCA alone.

Histological assessments
All patients underwent liver biopsy for diagnostic purposes. All liver specimens were histopathologically
evaluated by a single liver-specialised pathologist (YN). The severity of inflammation and fibrosis in AIH was graded according to the Ishak score.29 In brief, this grading system comprises four necroinflammatory categories: (1) periportal or periseptal interface hepatitis, (2) confluent necrosis, (3) focal lytic necrosis, apoptosis and focal inflammation and (4) portal inflammation; histological grading scores, which ranged from 0 to 18, were calculated by summing the scores for each category, and were graded in this study as follows: total score 0–3, A0; score 4–8, A1; score 9–12, A2 and score 13–18, A3.

Fibrosis stages ranged from 0 to 6, with stage 6 defined as liver cirrhosis.28 The histological staging and grading of PBC were assessed based on the Nakanuma’s classification.29,30 In brief, scores for fibrosis, bile duct loss and chronic cholestasis were summed for staging as follows: total score 0, stage 1 (no progression); score 1–3, stage 2 (mild progression); score 4–6, stage 3 (moderate progression); and score 7–9, stage 4 (advanced progression). Cholangitis activity (CA) and hepatitis activity (HA) were graded as CA0–3 and HA0–3, respectively. The histological staging and grading of OS were assessed based on both the Ishak score and Nakanuma’s classification.

Detection of miRNAs in liver tissues by in situ hybridisation
To evaluate the expression of miRNAs in the liver, in situ hybridisation was performed using a RiboMap in situ hybridisation kit (Ventana Medical Systems, Tucson, AZ) on a Ventana Discovery automated in situ hybridisation instrument (Ventana Medical Systems). Digoxigenin-labelled, LNA-modified DNA probes against miR-3196, miR-6125, miR-4725–3p, miR-4634 and scramble siRNA were obtained from Exiqon (Exiqon, Vedbaek, Denmark). In situ hybridisation steps after the deparaffinisation step were performed based on the standard protocol provided in the manufacturer’s RiboMap application note (http://www.ventanamed.com). The initial fixation step was performed by incubating the sections in a formalin-based RiboPrep reagent (Ventana Medical Systems) for 32 min at 37°C. After acid treatment using a hydrochloride-based RiboClear reagent (Ventana Medical Systems) for 12 min at 37°C, the slides were treated with a ready-to-use protease 2 reagent after an initial cell conditioning CC2 reagent (Ventana Medical Systems) for 8 min at 90°C. The initial denaturing prehybridisation step was done on the sections for 8 min at 91°C after being hybridised with an anti-sense LNA ribo-probe (5 pmol/slide) using a RiboHybe hybridisation buffer (Ventana Medical Systems) for 10 hours at 55°C. After three stringency washes with 2×RiboWash (Ventana Medical Systems) for 4 min at 51°C, postprobe fixation was performed using a RiboFix reagent for 20 min at 37°C, followed by incubation of antidigoxigenin alkaline phosphatase Fab fragments 1:800 (Roche) for 30 min at 37°C. A signal was detected using a BlueMap NBT/BCIP substrate kit for 4 hours at 37°C. Finally, the sections were counterstained with Kernechtrot (nuclear fast red) as a marker stain and covered with a glass coverslip.

Analysis of miRNA expression by microarray
Our standard operating procedures for miRNA microarray analysis have been previously published.31–34 In brief, total RNA was extracted from 300 µL serum samples obtained from patients with AIH, PBC and OS, and from healthy individuals using a 3D-Gene RNA extraction reagent (Toray Industries, Tokyo, Japan). Comprehensive miRNA expression analysis was performed using the 3D-Gene miRNA labelling kit and the 3D-Gene Human miRNA Oligo Chip (Toray Industries), designed to detect 2588 miRNAs registered in the miRBase release 21 database (http://www.mirbase.org/). To normalise microarray signals, three preselected internal control miRNAs (miR-149–3p, miR-2861, and miR-4463) were used. All microarray data from this study are publicly available in the GEO database (accession #GSE-140249) (https://www.ncbi.nlm.nih.gov/geo/).

Statistical analysis
Serum samples from patients with AIH and PBC were divided into the discovery and test cohorts. The discovery cohort was used to select candidate miRNAs that could discriminate between AIH and PBC, and the test cohort was used to confirm the results obtained from the discovery cohort. In this study, miRNAs with median signal values ≥2 were defined as abundant miRNAs in serum and were included in subsequent analyses. To identify robust biomarkers that could discriminate between AIH and PBC, a cross-validation score was calculated for each miRNA in the discovery set. This score was based on leave-one-out cross-validation and obtained by summing the results (hit or not) of each leave-out sample and dividing it by the number of repeats (the same as total sample number), as previously described.34 miRNAs with cross-validation scores >0.8 were selected for further analyses. The diagnostic sensitivity, specificity and area under the curve (AUC) were calculated for the selected miRNAs. In the test set, we determined the performances of the selected miRNAs in discriminating between AIH and PBC, and miRNAs with AUC >0.8 were considered to be AIH-specific.

Statistical analyses were performed using R V3.1.2 (R Foundation for Statistical Computing, http://www.R-project.org), compute.es package V0.2–4, hash package V2.2.6, MASS package V7.3–45, mutoss package V0.1–10, pROC package V1.8 and IBM SPSS Statistics V22 (IBM Japan, Tokyo, Japan). Principal component analysis (PCA) was performed using the Partek Genomics Suite version 6.6. Continuous variables were presented as mean±SD. Unpaired and paired t-tests were used to evaluate the differences in the distribution of continuous variables between the two groups. The Fisher’s exact test was used to evaluate the significance of differences in the distribution of categorical variables between the two groups. Correlations between variables were analysed using the Pearson’s correlation test.
RESULTS
Characteristics of the study participants
A total of 142 samples consisting of 49 samples from 28 patients with AIH (including 21 paired samples), 52 samples from 29 patients with PBC (including 23 paired samples), 14 samples from 7 patients with OS (including 7 paired samples), and 27 samples from 27 healthy controls (online supplemental table S1) were subjected to miRNA microarray analysis. First, untreated AIH and PBC samples were classified into the discovery and test sets. Paired serum samples were obtained from 21 treated patients with AIH, 23 treated patients with PBC, 7 patients with overlap syndrome, and 27 healthy individuals (controls). Regarding treatment response, all patients with AIH (n=21) met the remission criteria, and all patients with PBC (n=23) were biochemical responders. Among the seven patients with OS, four had already been receiving treatment for either PBC or OS and developed acute exacerbation of liver disease when the first samples were collected. For the management of disease exacerbation, prednisolone was added to the preceding UDCA monotherapy in three patients, and its dose was increased in one patient who was on UDCA and prednisolone combination therapy. The remaining three patients were newly diagnosed with OS and were treatment-naïve. All patients with OS had normalised ALT and ALP levels after the treatment, and only one had elevated IgG levels despite the treatment.

Identification of highly expressed miRNAs in AIH
The expression levels of 2588 miRNAs were comprehensively evaluated in the miRNA microarray analysis. First, 2259 miRNAs with a median signal value ≤ 2^6 in less than 50% of the samples were excluded. The remaining 329 miRNAs were retained for further analyses (figure 1B). PCA mapping was performed to assess the miRNA expression patterns in
the discovery set (figure 1C), indicating that there were distinct differences in the miRNA expression profile between AIH and PBC.

Subsequently, miRNAs that could discriminate AIH from PBC were investigated based on leave-one-out cross-validation, and 11 miRNAs (10 elevated in AIH and one elevated in PBC) with cross-validation scores >0.8 in the discovery set were selected (figure 1B, table 1). Finally, the diagnostic performance of these 11 miRNAs was assessed in the test set, and 4 miRNAs (miR-3196, miR-6125, miR-4725–3p and miR-4634) were highly accurate in discriminating AIH from PBC, with AUCs >0.8 (figure 1B, table 1). The AUC, sensitivity and specificity values for the four miRNAs were determined in the test set: miR-3196 had 0.90, 0.80 and 1.00, respectively; miR-6125 had 0.90, 0.80 and 0.88, respectively; miR-4725–3p had 0.88, 1.00 and 0.88, respectively; and miR-4624 had 0.98, 1.00 and 0.88, respectively (figure 2A).

**Changes in circulating miRNA expression levels after treatment**

Changes in the expression levels of the four miRNAs prior to and after treatment in patients with AIH, PBC and OS and healthy controls were evaluated using microarray data (figure 2B). The median expression levels of the four miRNAs were highest in pretreatment AIH samples, followed by those in OS samples collected at disease diagnosis or exacerbation. More importantly, the expression levels of these miRNAs (except miR-4725–3p in OS patients) significantly decreased in posttreatment AIH and OS samples. These findings suggest that these miRNAs reflect the disease activity of AIH and that OS may dominantly involve AIH features.

**Correlation between circulating miRNA expression and liver function parameter levels**

The correlation between the expression levels of the four miRNAs and liver function parameters was investigated (figure 2C). Their expression levels had significant positive correlations with the levels of aspartate aminotransferase (p<0.001 for all; r=0.59, 0.52, 0.48, and 0.60 for miR-3196, miR-6125, miR-4725–3p and miR-4634, respectively) and ALT (p<0.001 for all; r=0.56, 0.51, 0.54, and 0.61 for miR-3196, miR-6125, miR-4725–3p and miR-4634, respectively). The expression levels of miR-4634 and miR-3196 had significant negative correlations with albumin levels (p<0.001 and r = −0.43 for both).

**Localisation of the identified miRNAs in liver tissues**

In situ hybridisation was performed to determine the localisation of the four miRNAs in liver tissues. Diffused expressions of the four miRNAs were observed in the cytoplasm of hepatocytes in patients with AIH (figure 3B). miR-3196 and miR-6125 were very strongly stained, while miR-4725–3p and miR-4634 were moderately stained. In patients with PBC and OS, these miRNAs were also expressed in the cytoplasm of hepatocytes, but their expression levels were considerably lower than those in patients with AIH (figure 3A, C). miR-3196 was strongly stained, miR-6125 was moderately stained, while miR-4725–3p and miR-4634 were very weakly stained. In contrast, the expression of these miRNAs was almost undetectable in control liver tissues (figure 3D).

**Relationship between circulating miRNA expression levels and histological findings**

The correlation between the expression levels of the four miRNAs and hepatic necroinflammation/fibrosis...
in patients with AIH and OS was assessed (Figure 4A). The median expression levels of miR-3196, miR-6125, miR-4725–3p and miR-4634 in the necroinflammatory activity grade A3 group were distinctly higher than those in the grade A0–A2 groups. In contrast, no correlation was found between miRNA expression levels and fibrosis stages.

It was also evaluated whether the expression levels of the four miRNAs were correlated with histological parameters. ALB, albumin; ALP, alkaline phosphate; ALT, alanine aminotransferase; AST, aspartate aminotransferase; \( \gamma \)-GTP, \( \gamma \)-glutamyltransferase; PLT, platelet; TB, total bilirubin.
severity scores in patients with PBC and OS (Figure 4B). The median expression levels of miR-3196, miR-6125, and miR-4634 significantly increased in a stepwise manner with an increase in hepatitis activity scores. In contrast, the median expression levels of miR-6125 significantly decreased in a stepwise manner with an increase in cholangitis activity. Taken together, these findings suggest that the expression levels of miR-3196, miR-6125, and miR-4634 were positively associated with hepatocellular inflammatory activity.

**DISCUSSION**

miRNAs regulate the activities of immune cells, such as B, T and dendritic cells. Dysregulated miRNAs are involved in the pathogenesis of autoimmune diseases. Circulating miRNAs could serve as biomarkers for the diagnosis and staging/grading of various diseases, including autoimmune disease. However, an extensive analysis of circulating miRNAs in AIH has not sufficiently proceeded because AIH is relatively rare, so samples are difficult to obtain. In this study, the miRNA expression profiles between untreated patients with AIH and PBC were compared using a highly sensitive miRNA microarray technology; the four circulating miRNAs (miR-3196, miR-6125, miR-4725-3p and miR-4634) were identified as highly expressed in untreated patients with AIH, and these could discriminate AIH from PBC with high sensitivity and specificity. Of note, their circulating levels in patients with AIH drastically decreased after prednisolone treatment. Furthermore, in situ hybridisation analysis revealed that the four miRNAs were very strongly or moderately expressed in the cytoplasm of hepatocytes in untreated patients with AIH. Given that it is generally challenging to determine cells that release circulating miRNAs, this new finding that the four miRNAs are released by hepatocytes will be meaningful when they are identified as other disease biomarkers. These results suggest that the four miRNAs are closely associated with the pathogenesis of AIH and may be potential biomarkers for disease activity.

A previous study reported that 11 circulating miRNAs were up-regulated in untreated patients with AIH compared with healthy controls. Among the 11 miRNAs, miR-21-5p and miR-122-5p levels decreased in the remission phase after treatment. However, another study reported that these two miRNAs were also upregulated in patients with PBC, suggesting that both might not be specific for AIH. In this study, we failed to find the upregulated expression of the two miRNAs. Conversely, none of the 10 miRNAs up-regulated in our discovery set were increased in the previous study. There may be several possible explanations for these differences. First, the previous study only included a small number of patients with acute-onset AIH alone (n=5), and AIH-specific miRNAs were identified by comparing patients with AIH to healthy controls (not including patients with PBC). Second, our study included 28 patients with AIH (23 discovery and five test) with various disease stages and...
activities and compared them to patients with PBC and OS, as well as healthy controls. Third, despite the same microarray system, we normalized the miRNA signals using three unique internal controls (miR-149–3p, miR-2861 and miR-4463), which are stably expressed in any samples. Lastly, we excluded miRNAs with signal values <26 because candidate miRNAs should have a certain expression level as a disease-specific biomarker.

We also focused on the expression patterns of the four miRNAs in patients with OS with both AIH and PBC features. Their median levels were highest in untreated patients with AIH, followed by those in untreated patients with OS. Additionally, their expression levels drastically decreased after prednisolone treatment in patients with AIH and moderately declined in patients with OS after the initial or additional treatment or increased dose.
of prednisolone. In contrast, their expression levels in untreated patients with PBC did not significantly change despite the treatment. These findings suggest that the expression levels of the four miRNAs are indicative of AIH-related and treatment-responsive disease activity.

This study demonstrated that the median levels of the four miRNAs were highest in untreated patients with AIH, especially in those with necroinflammatory activity grade A3, and these increased in a stepwise manner with an increase in hepatitis activity in untreated patients with PBC and OS. Their expression levels significantly decreased after prednisolone treatment; however, the reduced levels were still higher compared with those in healthy controls, suggesting that hepatic necroinflammation may still continue even in the remission phase of AIH. Previous studies reported that approximately half of AIH patients with biochemical remission after immunosuppressive treatment showed persistent histological activity on second liver biopsy specimens, which was associated with fibrosis progression and poor prognosis. Therefore, they suggested that follow-up liver biopsy should be considered even in AIH patients with clinical remission. However, liver biopsy is invasive and a burden to patients, making it difficult to obtain a consent for repeat liver biopsy, especially in patients with clinical remission. The circulating miRNAs may serve as non-invasive surrogate biomarkers to estimate the persistence or disappearance of histological activity and to formulate therapeutic strategies, such as dose reduction or withdrawal of immunosuppressive agents.

This study had several limitations. First, little is known about the biological and physiological properties of the four miRNAs identified in this study. Most studies on these miRNAs have focused on their role and behaviour exclusively in malignant tumours, and no studies have investigated their involvement in the pathogenesis and clinical significance in autoimmune liver diseases. Accordingly, the four miRNAs may represent novel biomarkers of hepatic inflammatory activity in AIH. Second, this study included a small number of patients (especially in the test set) and no patients with other liver diseases, such as viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. Therefore, it is unclear whether the four miRNAs reflect AIH-specific or non-specific inflammatory activity. Third, although the in situ hybridisation revealed that the four miRNAs were highly expressed in the cytoplasm of hepatocytes in patients with AIH, it is unclear whether the upregulation of these miRNAs is involved in the development of AIH or is a result of hepatic necroinflammation. A large-scale validation study that includes other liver diseases is required to determine whether the four miRNAs are specific and useful biomarkers to estimate the disease activity of AIH. In addition, functional analyses, including the identification of target genes and mechanisms underlying autoimmune liver disease, are required to clarify the biological and physiological properties of these miRNAs.

In conclusion, we identified the four circulating miRNAs that could serve as non-invasive biomarkers associated with hepatic necroinflammatory activity in patients with AIH, using a comprehensive and highly sensitive miRNA microarray technology. These findings may be helpful in elucidating the mechanisms involved in the pathogenesis of AIH and in developing therapeutic strategies for it.

**Author affiliations**

1. Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan
2. Division of Gastroenterology, Department of Internal Medicine, Fuji City General Hospital, Shizuoka, Japan
3. Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo, Japan
4. Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan
5. Core Research Facilities, Research Center for Medical Science, The Jikei University School of Medicine, Tokyo, Japan
6. Department of Diagnostic Pathology, Fukui Prefecture Saiseikai Hospital, Fukui, Japan
7. Department of Molecular and Cellular Medicine, Tokyo Medical University, Tokyo, Japan
8. Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan
9. Toray Industries, Kanagawa, Japan

**Contributors** CS, JM and TO participated in the study conception and design. CS, KT, TOI and MS collected, analysed and interpreted the data. JM, MI and ST performed the experiments and analysed the data. YN evaluated the histological findings. MK and KF performed the in situ hybridisation. CS, JM and AT drafted the manuscript. AT interpreted the data and revised the manuscript extensively. AT substantively revised and completed the manuscript. CS is responsible for the overall content as guarantor.

**Funding** This study was supported by a Development of Diagnostic Technology for Detection of miRNA in Body Fluids grant from the Japan Agency for Medical Research and Development and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Science and Technology in Japan.

**Competing interests** MI and ST are employees of Toray Industries, the provider of the 3D-Gene system. The other authors declare no conflicts of interest.

**Patient consent for publication** Consent obtained directly from patient(s).

**Ethics approval** This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Jikei University School of Medicine (approval No. 28-318, No. 30-051) and Fuji City General Hospital (approval No. 159).

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data availability statement** Data are available on reasonable request.

**Supplemental material** This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**ORCID iD**

Chisato Saeki http://orcid.org/0000-0002-7407-6142
REFERENCES
1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54–66.
2. Czaja AJ. Diagnosis and management of autoimmune hepatitis: current status and future directions. Gut Liver 2016;10:177–203.
3. Tanaka A. Autoimmune hepatitis: 2019 update. Gut Liver 2020;14:430–8.
4. Huang C, Xing X, Xiang X, et al. Micromonas in autoimmune liver diseases: from diagnosis to potential therapeutic targets. Biomed Pharmacother 2020;130:110588.
5. Sebode M, Hartl J, Vergani D, et al. Autoimmune hepatitis: from current knowledge and clinical practice to future research agenda. Liver Int 2018;38:15–22.
6. Manns MP, Czaja AJ, Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193–213.
7. Lüth S, Herkel J, Kanzler S, et al. Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis. J Clin Gastroenterol 2008;42:926–30.
8. Dhaliwal HK, Hoenoldt BS, Dube AK, et al. Long-Term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis. Am J Gastroenterol 2015;110:993–9.
9. Engel B, Taubert R, Jaeckel E, et al. The future of autoimmune liver diseases - Understanding pathogenesis and improving morbidity and mortality. Liver Int 2020;40 Suppl 1:149–53.
10. Selmi C, Bowlus CL, Gershwin ME, et al. Primary biliary cirrhosis. Lancet 2011;377:1600–9.
11. Lleo A, Marzorati S, Anaya J-M, et al. Primary biliary cholangitis: a comprehensive overview. Hepatol Int 2017;11:485–99.
12. Working Group (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: the intractable hepatobiliary disease Study Group supported by the Ministry of health, labour and welfare of Japan. Hepatol Res 2014;44 Suppl 5:1–90.
13. Boberg KM, Chapman RW, Hirschfield GM, et al. Overlap syndromes: the International autoimmune hepatitis group (IAIHG) position statement on a controversial issue. J Hepatol 2011;54:374–85.
14. Czaja AJ. The overlap syndromes of autoimmune hepatitis. Dig Dis Sci 2013;58:326–43.
15. Chazoulières O, Wendum D, Serfaty L, et al. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998;28:296–301.
16. Silveira MG, Talwalkar JA, Hengguo P, et al. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes. Am J Gastroenterol 2007;102:1244–50.
17. O’Connell RM, Rao DS, Chaudhuri AA, et al. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010;10:11–22.
18. Winter J, Jung S, Keller S, et al. Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009;11:228–34.
19. Bala S, Petrasek J, Mundkur S, et al. Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic drug-induced, and inflammatory liver diseases. Hepatology 2012;56:1946–57.
20. Szabo G, Bala S. Micromonas in liver disease. Nat Rev Gastroenterol Hepatol 2013;10:542–52.
21. Loosen SH, Schueller F, Trautwein C, et al. Role of circulating microRNAs in liver diseases. World J Hepatol 2017;9:586–94.
22. Migitata K, Komori A, Kozuru H, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One 2015;10:e0136908.
23. Tan Y, Pan T, Ye Y, et al. Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One 2014;9:e111424.
24. Zheng J, Li Z, Wang T, et al. Microarray expression profile of circulating RNAs in plasma from primary biliary cholangitis patients. Cell Physiol Biochem 2017;44:1271–81.
25. Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol 2016;185:61–71.
26. Alvarez F, Berg PA, Bianchi FB, et al. International autoimmune hepatitis group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–38.
27. Parès A, Caballeria L, Rodès J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130:715–20.
28. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696–9.
29. Hiramatsu K, Aoyama H, Zen Y, et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology 2006;49:466–78.
30. Nakamura Y, Zen Y, Harada K, et al. Application of a new histological grading and staging system for primary biliary cirrhosis to liver biopsy specimens: interobserver agreement. Pathol Int 2010;60:167–74.
31. Usuba W, Urabe F, Yamamoto Y, et al. Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci 2014;110:409–19.
32. Shiino S, Matsuizaki J, Shimomura A, et al. Serum miRNA-based prediction of axillary lymph node metastasis in breast cancer. Clin Cancer Res 2019;25:1817–27.
33. Yokoi A, Matsuizaki J, Yamamoto Y, et al. Integrated extracellular microRNA profiling for ovarian cancer screening. Nat Commun 2018;9:4319.
34. Urabe F, Matsuizaki J, Yamamoto Y, et al. Large-Scale circulating microRNA profiling for the liquid biopsy of prostate cancer. Clin Cancer Res 2019;25:3016–25.
35. Zhang L, Wu H, Zhao M, et al. Clinical significance of miRNAs in autoimmune, J Autoimmun 2020;109:105438.
36. Zhou Z, Sun B, Huang S, et al. Roles of circular RNAs in immune regulation and autoimmune diseases. Cell Death Dis 2019;10:503.
37. Sudo K, Kato K, Matsuizaki J, et al. Development and validation of an esophageal squamous cell carcinoma detection model by large-scale microRNA profiling. JAMA Netw Open 2019;2:e194573.
38. Ho K-H, Chang C-K, Chen P-H, et al. miR-4725-3p targeting stromal interacting molecule 1 signaling is involved in xanthohumol inhibition of glioma cell invasion. J Neurochem 2018;146:869–88.
39. Shimomura A, Shiino S, Kawauchi J, et al. Novel combination of serum microRNA for detecting breast cancer in the early stage. Cancer Sci 2016;107:326–34.